USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ANDROBIOSYS, INC.
City: BUFFALO
State: NY
Zip+4: 14203-1070
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $417,991.00 3
SBIR Phase II $999,642.00 1
STTR Phase I $96,765.00 1
STTR Phase II $747,553.00 1

Award List:

Circulating Prostate Cancer Progenitor Cell Assay Development

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency / Branch: DOD / ARMY
Research Institution: ROSWELL PARK CANCER INSTITUTE
Principal Investigator: Michael Zwick, CEO
Award Amount: $96,765.00
RI Contact: Joseph H. Jurkowski
Abstract:
This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate progenitor cells. The eventual goal of this work would be to develop a high throughput blood-based… More

PLATELET-BASED NANOPARTICLE THERAPY FOR PROSTATE CANCER

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael Zwick
Award Amount: $149,994.00
Abstract:
The goal of this proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix par ticles) that contains super paramagnetic… More

Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael G. Zwick
Award Amount: $128,052.00
Abstract:
DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatment modalities include alpha-blockers that do not affect the underlying pathologic process, and… More

Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael G. Zwick
Award Amount: $139,945.00
Abstract:
DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the techno logy for reproducible implantation of… More

Platelet-based Nanoparticle Therapy for Prostate Cancer

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael Zwick
Award Amount: $999,642.00
Abstract:
The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super… More

Circulating Prostate Cancer Progenitor Cell Assay Development

Award Year / Program / Phase: 2011 / STTR / Phase II
Agency / Branch: DOD / ARMY
Research Institution: Roswell Park Cancer Institute
Principal Investigator: Michael G. Zwick, CEO – (716) 860-7920
Award Amount: $747,553.00
RI Contact: John T. Blandino
Abstract:
The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cells. We propose to utilize the information from the Phase I award and subsequent research to develop… More